3,331 results on '"Lam, Carolyn"'
Search Results
52. Statins and risks of dementia among patients with heart failure: a population-based retrospective cohort study in Hong Kong
53. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
54. Heart failure with mildly reduced ejection fraction
55. Predictors of adverse diastolic remodeling in non-diabetic patients presenting with ST-elevation myocardial infarction
56. Challenges and opportunities for increasing patient involvement in heart failure self-care programs and self-care in the post–hospital discharge period
57. Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial
58. Diabetes and risk of heart failure in people with and without cardiovascular disease: systematic review and meta-analysis
59. Toward a Universal Definition of Etiologies in Heart Failure: Categorizing Causes and Advancing Registry Science
60. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial
61. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study
62. Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial
63. Clinical Features of Heart Failure With Normal Ejection Fraction: Insights From the ASIAN-HF Registry
64. Asia-Pacific Investigators and Asian Enrollment in Cardiometabolic Trials: Insights From Publications Between 2011 and 2020
65. Changing health related quality of life and outcomes in heart failure by age, sex and subtype
66. The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF
67. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status
68. Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry
69. Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial
70. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER
71. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
72. Association Between Diabetes, Chronic Kidney Disease, and Outcomes in People With Heart Failure From Asia
73. Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial
74. Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
75. Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF
76. Fully Automated Artificial Intelligence Assessment of Aortic Stenosis by Echocardiography
77. Patient-Reported Status and Heart Failure Outcomes in Asia by Sex, Ethnicity, and Socioeconomic Status
78. How to Manage Heart Failure With Preserved Ejection Fraction: Practical Guidance for Clinicians
79. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
80. Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity
81. Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort Analysis
82. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
83. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA
84. Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective Cohort
85. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
86. Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF
87. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy
88. Incidence, Clinical Correlates, and Prognostic Impact of Dementia in Heart Failure: A Population-Based Cohort Study
89. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy
90. Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week
91. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER
92. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
93. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
94. Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis
95. Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation
96. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial
97. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
98. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
99. Role of Cardiac Contractility Modulation in Heart Failure With a Higher Ejection Fraction
100. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.